Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Haemodialysis Patients (Genius)
Retrospective Analysis of Performance and Treatment Data Collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in Acute Haemodialysis, Haemodynamically Instable Patients and Chronic Haemodialysis Patients
Retrospective analysis of performance and treatment data collected for Genius SleddFlux Filter, Ultraflux AV 600 S Filter & Genius 90 Concentrates in acute haemodialysis, haemodynamically instable patients and chronic haemodialysis patients
- to analyse performance and treatment data from patients treated with the investigational device
- to evaluate the filter characteristics for aHD (Acute haemodialysis) patients
- to evaluate the improvement of kidney function for aHD patients
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Tatiana De los Rios
- Phone Number: +49 6172 608 2362
- Email: Tatiana.De-Los-Rios@fmc-ag.com
Study Contact Backup
- Name: Jana Schmitt
- Phone Number: +49 6172 609 95403
- Email: Jana.Schmitt@fmc-ag.com
Study Locations
-
-
-
Berlin, Germany, 12683
- BG Klinikum Unfallkrankenhaus Berlin gGmbH
-
Hanover, Germany, 30625
- Medizinische Hochschule Hannover
-
Jena, Germany, 07743
- Universitatsklinikum Jena
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients with an indication for the extracorporeal blood treatment suffering from renal insufficiency who received all treatments, between January 2019 and December 2019, with the investigational devices have to be included in the study in chronological order.
- For aHD patients: availability of at least 3 of the 5 primary variables (daily urea, creatinine, potassium, ultrafiltration and effluent volume) for 50 % of the documented treatments.
- For cHD patients: availability of the ultrafiltration values for all treatments and at least one value for urea and creatinine per week
Exclusion Criteria:
- Simultaneous use of another filter/adsorber for another form of therapy
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
aHD: Acute haemodialysis patients
|
|
cHD: Chronic haemodialysis patients
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Daily values for urea, Unit: mg/dl or mmol/L
Time Frame: During the intervention
|
Acute haemodialysis patients
|
During the intervention
|
|
Daily values for creatinine, Unit: mg/dl or mmol/ or µmol/L
Time Frame: During the intervention
|
Acute haemodialysis patients
|
During the intervention
|
|
Daily values for potassium, Unit: mg/dl or mmol/ or µmol/L
Time Frame: During the intervention
|
Acute haemodialysis patients
|
During the intervention
|
|
Ultrafiltration volume (UF) and Effluent volume (per treatment)
Time Frame: During the intervention
|
Acute haemodialysis patients
|
During the intervention
|
|
Values for urea and creatinine (measured according to the clinical practice of the site)
Time Frame: During the intervention
|
Chronic haemodialysis patients
|
During the intervention
|
|
Planned and delivered UF-volume (per treatment)
Time Frame: During the intervention
|
Chronic haemodialysis patients
|
During the intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Bernhard Schmidt, Prof Dr med, Hannover Medical School
- Principal Investigator: Martin Brauer, Dr. med., Jena University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urogenital Diseases
- Pathologic Processes
- Male Urogenital Diseases
- Kidney Diseases
- Urologic Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Chronic Disease
- Disease Attributes
- Renal Insufficiency, Chronic
- Pathological Conditions, Signs and Symptoms
- Acute Kidney Injury
- Renal Insufficiency
- Kidney Failure, Chronic
Other Study ID Numbers
Other Study ID Numbers
- Genius-AKI-01-D
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.